Treatable Traits in Chronic Respiratory Disease: A Comprehensive Review

Lee, Yong Qin; Selvakumar, A; See, Kay Choong

doi:10.3390/cells10113263

Cited by 7 publications

(3 citation statements)

References 58 publications

(114 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The FEV1/FVC ratio <0.7 serves as a vital biomarker for airflow limitation. Interventions, including β2-agonists and antimuscarinic agents, aim to optimize bronchodilation, enhance airflow, improve overall respiratory function, and enhance the ability to perform daily activities with ease [ 21 , 22 ].…”

Section: Reviewmentioning

confidence: 99%

Phenotype to Treatable Traits-Based Management in Chronic Obstructive Pulmonary Disease

Kumar,

Kant,

Niranjan

2024

Cureus

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD), a heterogeneous respiratory disease driven by various genetic and environmental factors, presents significant challenges in diagnosis and management. Traditional approaches focused on phenotypic classification, but recent paradigms emphasize identifying and addressing treatable traits to personalize treatment strategies. Treatable traits facilitate personalized interventions, optimizing symptom control, and reducing exacerbation risk. Dyspnea and exacerbations, recognized as key traits, guide treatment decisions and follow-up management. Various interventions, including bronchodilators, corticosteroids, and lifestyle modifications, target specific traits like airway inflammation, mucus overproduction, and emphysema. Strategies for assessing and addressing treatable traits during initial encounters and follow-up visits enhance disease monitoring and treatment efficacy. Comprehensive trait assessment demands resources and specialized monitoring, posing barriers to widespread implementation. The lack of standardized protocols and evolving evidence further complicates decision-making and clinical practice. Despite these challenges, the shift toward treatable traits-based management signifies a pivotal advancement in COPD care, emphasizing holistic approaches tailored to individual patient needs. Recognizing and addressing treatable traits offers personalized interventions, enhancing symptom control and disease management. Embracing treatable traits-based approaches holds promise for improving clinical outcomes and enhancing the quality of life for individuals living with COPD.

show abstract

Section: Reviewmentioning

confidence: 99%

Phenotype to Treatable Traits-Based Management in Chronic Obstructive Pulmonary Disease

Kumar,

Kant,

Niranjan

2024

Cureus

View full text Add to dashboard Cite

show abstract

“…Holistic management of environmental triggers and comorbid conditions such as obesity, obstructive sleep apnea, cardiac dysfunction, anxiety, and depression can be considered as part of a “treatable traits” approach to improve the care of patients with chronic respiratory disease, further reducing the need for high dose ICS/INS. Using this approach, physiological, biochemical, psychosocial, microbiological, and comorbidity traits are targeted with both pharmacological and non-pharmacological interventions[ 30 ].…”

Section: Reducing the Impact Of Ics And Ins On Glucose Metabolism And Dmmentioning

confidence: 99%

Impact of inhaled and intranasal corticosteroids on glucose metabolism and diabetes mellitus: A mini review

See¹

2023

World J Diabetes

Self Cite

View full text Add to dashboard Cite

The incidence of type 2 diabetes mellitus is growing in epidemic proportions and has become one of the most critical public health concerns. Cardiovascular complications associated with diabetes are the leading cause of morbidity and mortality. The cardiovascular diseases that accompany diabetes include angina, myocardial infarction, stroke, peripheral artery disease, and congestive heart failure. Among the various risk factors generated secondary to hyperglycemic situations, advanced glycation end products (AGEs) are one of the important targets for future diagnosis and prevention of diabetes. In the last decade, AGEs have drawn a lot of attention due to their involvement in diabetic patho-physiology. AGEs can be derived exogenously and endogenously through various pathways. These are a nonhomogeneous, chemically diverse group of compounds formed nonenzymatically by condensation between carbonyl groups of reducing sugars and free amino groups of protein, lipids, and nucleic acid. AGEs mediate their pathological effects at the cellular and extracellular levels by multiple pathways. At the cellular level, they activate signaling cascades via the receptor for AGEs and initiate a complex series of intracellular signaling resulting in reactive oxygen species generation, inflammation, cellular proliferation, and fibrosis that may possibly exacerbate the damaging effects on cardiac functions in diabetics. AGEs also cause covalent modifications and cross-linking of serum and extracellular matrix proteins; altering their structure, stability, and functions. Early diagnosis of diabetes may prevent its progression to complications and decrease its associated comorbidities. In the present review, we recapitulate the role of AGEs as a crucial mediator of hyperglycemia-mediated detrimental effects in diabetes-associated complications. Furthermore, this review presents an overview of future perspectives for new therapeutic interventions to ameliorate cardiovascular complications in diabetes.

show abstract

“…The most common inflammatory lung diseases include pathogen-infected pneumonia, acute lung injury (ALI), and chronic obstructive pulmonary disease (COPD). Although many disease models have been widely reported for use in studying the mechanisms of inflammation, there are many limitations in their applications, and it is, therefore, necessary to find a disease research model that can be fully modeled in vitro as soon as possible [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

Application of Precision-Cut Lung Slices as an In Vitro Model for Research of Inflammatory Respiratory Diseases

Liu

Wang

et al. 2022

Bioengineering

View full text Add to dashboard Cite

The leading cause of many respiratory diseases is an ongoing and progressive inflammatory response. Traditionally, inflammatory lung diseases were studied primarily through animal models, cell cultures, and organoids. These technologies have certain limitations, despite their great contributions to the study of respiratory diseases. Precision-cut lung slices (PCLS) are thin, uniform tissue slices made from human or animal lung tissue and are widely used extensively both nationally and internationally as an in vitro organotypic model. Human lung slices bridge the gap between in vivo and in vitro models, and they can replicate the living lung environment well while preserving the lungs’ basic structures, such as their primitive cells and trachea. However, there is no perfect model that can completely replace the structure of the human lung, and there is still a long way to go in the research of lung slice technology. This review details and analyzes the strengths and weaknesses of precision lung slices as an in vitro model for exploring respiratory diseases associated with inflammation, as well as recent advances in this field.

show abstract

Treatable Traits in Chronic Respiratory Disease: A Comprehensive Review

Cited by 7 publications

References 58 publications

Phenotype to Treatable Traits-Based Management in Chronic Obstructive Pulmonary Disease

Phenotype to Treatable Traits-Based Management in Chronic Obstructive Pulmonary Disease

Impact of inhaled and intranasal corticosteroids on glucose metabolism and diabetes mellitus: A mini review

Application of Precision-Cut Lung Slices as an In Vitro Model for Research of Inflammatory Respiratory Diseases

Contact Info

Product

Resources

About